Med Biogene (MBI) Reaches New 12-Month Low at $0.05
Med Biogene Inc (CVE:MBI) hit a new 52-week low during trading on Monday . The stock traded as low as C$0.05 and last traded at C$0.05, with a volume of 7000 shares. The stock had previously closed at C$0.05.
Med Biogene Company Profile (CVE:MBI)
Med BioGene Inc, a life science company, focuses on the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer. Its products include the GeneFx Lung, a gene expression-based test for early-stage non-small-cell lung cancer that assists in identifying patients for adjuvant chemotherapy.
See Also: What is the balance sheet?
Receive News & Ratings for Med Biogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Med Biogene and related companies with MarketBeat.com's FREE daily email newsletter.